{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:34Z","timestamp":1792207594505,"version":"4.4.0"},"reference-count":131,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The treatment landscape of B-cell non-Hodgkin lymphomas is rapidly evolving. However, few advances have occurred in marginal zone lymphoma (MZL), with a single US Food and Drug Administration\u2013approved agent impacting the treatment landscape. Multiple factors are associated with this slower pace of progress, with a lower MZL incidence representing a significant factor. Pivotal randomized indolent lymphoma clinical trials analyzed MZL subsets without the appropriate power to capture differences between treatment arms. Furthermore, the current Lugano classification may not fully capture the presentation or treatment responses of some subtypes, preventing access to clinical trials and limiting an efficacy assessment across the disease spectrum. Thus, current MZL treatment is largely informed by single-arm studies with relatively empiric treatment sequencing among available agents. Although frontline strategies in early and advanced-stage MZL can achieve prolonged disease control, few options exist in the relapsed\/refractory setting capable of achieving similar results. Emerging data demonstrate the encouraging efficacy of CD3\u00d7CD20 bispecific antibodies and antibody-drug conjugates in achieving deep responses, as well as the potential of circulating tumor DNA in risk stratification and molecular response monitoring. Compounding all these considerations, it is essential to recognize MZL as a heterogeneous group of diseases characterized by unique biology, clinical presentation, treatment response, toxicity, and survival. Nonetheless, a common characteristic across MZL subtypes is their general indolent disease course, emphasizing the need to incorporate patient-centered assessment in clinical trials to better inform the decision-making process.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024028269","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:56:41Z","timestamp":1752613001000},"page":"115-126","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["The treatment of marginal zone lymphoma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan Pablo","family":"Alderuccio","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"33","key":"2026010811215991600_bib1","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026010811215991600_bib2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026010811215991600_bib3","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol"},{"issue":"8","key":"2026010811215991600_bib4","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026010811215991600_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"2026010811215991600_bib6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026010811215991600_bib7","unstructured":"US Food and Drug Administration\n          . FDA granted accelerated approval to tazemetostat for follicular lymphoma. 2020. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma."},{"key":"2026010811215991600_bib8","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. 2024. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma."},{"key":"2026010811215991600_bib9","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. 2022. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma."},{"key":"2026010811215991600_bib10","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma. 2024. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma."},{"key":"2026010811215991600_bib11","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. 2024. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma."},{"key":"2026010811215991600_bib12","unstructured":"US Food and Drug Administration\n          . FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma. 2022. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma."},{"key":"2026010811215991600_bib13","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. 2021. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma."},{"issue":"8","key":"2026010811215991600_bib14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2026010811215991600_bib15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026010811215991600_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"22","key":"2026010811215991600_bib17","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"2026010811215991600_bib18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2026010811215991600_bib19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026010811215991600_bib20","unstructured":"US Food and Drug Administration\n          . FDA grants accelerated approval to zanubrutinib for marginal zone lymphoma. 2021. Accessed 13 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-marginal-zone-lymphoma."},{"issue":"4","key":"2026010811215991600_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of follicular lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026010811215991600_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"34","key":"2026010811215991600_bib23","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026010811215991600_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"issue":"16","key":"2026010811215991600_bib25","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1182\/bloodadvances.2024013499","article-title":"Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis","volume":"8","author":"Florindez","year":"2024","journal-title":"Blood Adv"},{"issue":"27","key":"2026010811215991600_bib26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026010811215991600_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2026010811215991600_bib28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"14","key":"2026010811215991600_bib29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026010811215991600_bib30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026010811215991600_bib31","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026010811215991600_bib32","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2026010811215991600_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026010811215991600_bib34","first-page":"206","article-title":"Current treatments in marginal zone lymphoma","volume":"36","author":"Alderuccio","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"19","key":"2026010811215991600_bib35","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1182\/blood.2024025794","article-title":"EMZL at various sites: learning from each other","volume":"145","author":"Du","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026010811215991600_bib36","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.3324\/haematol.2018.214957","article-title":"Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses","volume":"104","author":"Cascione","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2026010811215991600_bib37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026010811215991600_bib38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2021012386","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio","year":"2022","journal-title":"Blood"},{"issue":"35","key":"2026010811215991600_bib39","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.22.00668","article-title":"Direct-acting antivirals as primary treatment for hepatitis C virus-associated indolent non-Hodgkin lymphomas: the BArT study of the Fondazione Italiana Linfomi","volume":"40","author":"Merli","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026010811215991600_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJM199803193381205","article-title":"Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach","volume":"338","author":"Zucca","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"2026010811215991600_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site","volume":"165","author":"Khalil","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2026010811215991600_bib42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdp402","article-title":"Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2026010811215991600_bib43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/ajcp\/aqad088","article-title":"Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis","volume":"160","author":"Gu","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2026010811215991600_bib44","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"2026010811215991600_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"2026010811215991600_bib46","unstructured":"National Comprehensive Cancer Network\n          . Clinical Practice Guidelines in Oncology: B-cell lymphomas. Version 2, 2025. 2025. Accessed 13 February 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480."},{"issue":"9","key":"2026010811215991600_bib47","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"issue":"1","key":"2026010811215991600_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjh.12078","article-title":"Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice","volume":"160","author":"Copie-Bergman","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2026010811215991600_bib49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026010811215991600_bib50","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"issue":"8","key":"2026010811215991600_bib51","first-page":"2564","article-title":"IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma","volume":"109","author":"Stathis","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2026010811215991600_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026010811215991600_bib53","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(24)00133-9","article-title":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","volume":"11","author":"Gunther","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026010811215991600_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2016-05-714584","article-title":"Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study","volume":"129","author":"Desai","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026010811215991600_bib55","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2024.2112","article-title":"Response-adapted ultralow-dose radiation therapy for orbital indolent B-cell lymphoma: a phase 2 nonrandomized controlled trial","volume":"10","author":"Pinnix","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"2026010811215991600_bib56","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2026010811215991600_bib57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2005-06-2332","article-title":"Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci","volume":"107","author":"Rosado","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2026010811215991600_bib58","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2005.09.012","article-title":"Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience","volume":"30","author":"Vargas","year":"2006","journal-title":"Leuk Res"},{"issue":"5","key":"2026010811215991600_bib59","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.ijrobp.2025.03.011","article-title":"An International Lymphoma Radiation Oncology Group study of radiotherapy for bilateral indolent orbital adnexal lymphomas","volume":"22","author":"Tran","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2026010811215991600_bib60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ajh.26591","article-title":"Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma","volume":"98","author":"Saul","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2026010811215991600_bib61","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2015-0180","article-title":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41)","volume":"20","author":"Jackson","year":"2015","journal-title":"Oncologist"},{"issue":"4","key":"2026010811215991600_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.2243","article-title":"A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)","volume":"34","author":"Sammassimo","year":"2016","journal-title":"Hematol Oncol"},{"issue":"2","key":"2026010811215991600_bib63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/bloodadvances.2020003213","article-title":"Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue","volume":"5","author":"Joffe","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2026010811215991600_bib64","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00000478-200108000-00003","article-title":"Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type","volume":"25","author":"Kurtin","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"2026010811215991600_bib65","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1002\/cam4.3096","article-title":"Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis","volume":"9","author":"Husnain","year":"2020","journal-title":"Cancer Med"},{"issue":"11","key":"2026010811215991600_bib66","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1080\/10428194.2021.1933479","article-title":"Primary thyroid lymphoma: survival analysis of SEER database (1995-2016)","volume":"62","author":"Florindez","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026010811215991600_bib67","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/jc.2017-01478","article-title":"Long-term outcomes of 107 cases of primary thyroid mucosa-associated lymphoid tissue lymphoma at a single medical institution in Japan","volume":"103","author":"Watanabe","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2026010811215991600_bib68","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026010811215991600_bib69","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2026010811215991600_bib70","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets","volume":"34","author":"Edinger","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2026010811215991600_bib71","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/modpathol.2013.106","article-title":"Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression","volume":"26","author":"Brenner","year":"2013","journal-title":"Mod Pathol"},{"issue":"4","key":"2026010811215991600_bib72","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10428194.2016.1218006","article-title":"Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences","volume":"58","author":"de la Fuente","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026010811215991600_bib73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/cam4.2732","article-title":"An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement","volume":"9","author":"Sunderland","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"2026010811215991600_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2026010811215991600_bib75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11060-022-04052-1","article-title":"Chemotherapy is an efficient treatment in primary CNS MALT lymphoma","volume":"159","author":"Desjardins","year":"2022","journal-title":"J Neurooncol"},{"issue":"5","key":"2026010811215991600_bib76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.25446","article-title":"Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation","volume":"94","author":"Alderuccio","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2026010811215991600_bib77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2015.01.040","article-title":"Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent","volume":"92","author":"Teckie","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2026010811215991600_bib78","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers13081803","article-title":"Treatments and outcomes in stage I extranodal marginal zone lymphoma in the United States","volume":"13","author":"Alderuccio","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026010811215991600_bib79","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026010811215991600_bib80","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2022009587","article-title":"Retrospective characterization of nodal marginal zone lymphoma","volume":"7","author":"Stuver","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2026010811215991600_bib81","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.2019004588","article-title":"Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study","volume":"136","author":"Lo","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2026010811215991600_bib82","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026010811215991600_bib83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"2026010811215991600_bib84","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026010811215991600_bib85","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026010811215991600_bib86","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"2026010811215991600_bib87","first-page":"2297","article-title":"Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA\/IELSG36 phase II study","volume":"109","author":"Iannitto","year":"2024","journal-title":"Haematologica"},{"issue":"S2","key":"2026010811215991600_bib88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hon.40_2630","article-title":"Rituximab alone (r) versus rituximab plus bendamustine (br) for splenic (smzl) and nodal marginal zone lymphoma (nmzl)","volume":"37","author":"Olszewski","year":"2019","journal-title":"Hematological Oncol"},{"issue":"23","key":"2026010811215991600_bib89","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1182\/blood.V126.23.4167.4167","article-title":"Standard duration of varicella zoster virus prophylaxis may be inadequate to prevent viral reactivation in patients with chronic lymphocytic leukemia treated with front-line bendamustine plus rituximab [abstract]","volume":"126","author":"Allen","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2026010811215991600_bib90","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2026010811215991600_bib91","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"issue":"28","key":"2026010811215991600_bib92","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab (R(2)) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026010811215991600_bib93","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2024-205671","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes in patients with relapsed\/refractory follicular lymphoma [abstract]","volume":"144","author":"Iacoboni","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026010811215991600_bib94","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"2026010811215991600_bib95","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","article-title":"Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2026010811215991600_bib96","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2026010811215991600_bib97","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2026010811215991600_bib98","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.33117","article-title":"Splenic marginal zone lymphoma: A US population-based survival analysis (1999-2016)","volume":"126","author":"Florindez","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"2026010811215991600_bib99","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2026010811215991600_bib100","first-page":"439","article-title":"Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience","volume":"110","author":"Cassanello","year":"2025","journal-title":"Haematologica"},{"issue":"8","key":"2026010811215991600_bib101","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2026010811215991600_bib102","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","article-title":"Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma","volume":"7","author":"Nastoupil","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2026010811215991600_bib103","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026010811215991600_bib104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026010811215991600_bib105","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2023-180048","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed\/refractory marginal zone lymphoma: results from phase 1\/2 BRUIN study [abstract]","volume":"142","author":"Patel","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026010811215991600_bib106","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2024-193022","article-title":"Mosunetuzumab with response-driven lenalidomide augmentation as first-line therapy for symptomatic follicular or marginal zone lymphoma: interim analysis of a multi-center phase 2 atudy [abstract]","volume":"144","author":"Olszewski","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026010811215991600_bib107","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2024-200190","article-title":"Efficacy and safety of odronextamab in relapsed\/refractory marginal zone lymphoma (R\/R MZL): data from the R\/R MZL cohort in the ELM-2 study [abstract]","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026010811215991600_bib108","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026010811215991600_bib109","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2024-200205","article-title":"Limited duration loncastuximab tesirine induces a high rate of complete responses in patients with relapsed\/refractory marginal zone lymphoma - report of first planned interim futility analysis of a multicenter phase II study [abstract]","volume":"144","author":"Lossos","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026010811215991600_bib110","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2026010811215991600_bib111","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026010811215991600_bib112","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"2026010811215991600_bib113","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026010811215991600_bib114","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","article-title":"Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: a US multisite study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2026010811215991600_bib115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026010811215991600_bib116","first-page":"1466","article-title":"Reproducibility of m7-FLIPI risk scores in follicular lymphoma using tumor biopsies and blood specimens [abstract]","volume":"130","author":"Soo","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2026010811215991600_bib117","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2024-210085","article-title":"Genetic characterization of marginal zone lymphomas in tissue and cfDNA [abstract]","volume":"144","author":"Diez-Feij\u00f3o Varela","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026010811215991600_bib118","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1007\/s00259-022-05683-2","article-title":"Clinical and pathological predictors for FDG-PET\/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study","volume":"49","author":"Kagan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2026010811215991600_bib119","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.2578","article-title":"FDG PET\/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma","volume":"37","author":"Vaxman","year":"2019","journal-title":"Hematol Oncol"},{"issue":"3","key":"2026010811215991600_bib120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","article-title":"PET\/CT in non-Hodgkin lymphoma: an update","volume":"53","author":"Zanoni","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"11","key":"2026010811215991600_bib121","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/j.clml.2020.06.018","article-title":"Prognostic value of (18)F-FDG PET\/CT metabolic parameters in splenic marginal zone lymphoma","volume":"20","author":"Albano","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2026010811215991600_bib122","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hon.2181","article-title":"Role of 18F-FDG-PET\/CT in the management of marginal zone B cell lymphoma","volume":"33","author":"Carrillo-Cruz","year":"2015","journal-title":"Hematol Oncol"},{"issue":"8","key":"2026010811215991600_bib123","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.27712","article-title":"PET\/CT in the staging and treatment response assessment of patients with extranodal marginal zone lymphoma","volume":"100","author":"Alderuccio","year":"2025","journal-title":"Am J Hematol"},{"issue":"10","key":"2026010811215991600_bib124","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J Nucl Med"},{"issue":"23","key":"2026010811215991600_bib125","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026010811215991600_bib126","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026010811215991600_bib127","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026010811215991600_bib128","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2023-189824","article-title":"Phased variants allow robust profiling of circulating tumor DNA in untreated follicular lymphomas [abstract]","volume":"142","author":"Nagy","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026010811215991600_bib129","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1007\/s12325-024-02882-1","article-title":"Quality of life evaluation in patients with follicular cell lymphoma: a real-world study in Europe and the United States","volume":"41","author":"Johnson","year":"2024","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"2026010811215991600_bib130","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1182\/blood-2023-188382","article-title":"Frontline management strategy and quality of life in follicular lymphoma: a multi-institutional prospective cohort study [abstract]","volume":"142","author":"Tsang","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026010811215991600_bib131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/2\/115\/2478730\/blood_bld-2024-028269-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/2\/115\/2478730\/blood_bld-2024-028269-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:22:20Z","timestamp":1767889340000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/2\/115\/546195\/The-treatment-of-marginal-zone-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028269","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,8]]},"published":{"date-parts":[[2026,1,8]]}}}